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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Early gastric cancer is defined as adenocarcinoma limited to the mucosa and 
submucosa of the stomach, regardless of lymph node status. The entity is common 
in the Orient, where gastric cancer is a common cause of cancer death, and where 
aggressive surveillance programs have therefore been established. Approximately 
10% of patients with early gastric cancer will have lymph node metastases. There 
are several types and subtypes of early gastric cancer.  
 
Approximately 70% of early gastric cancers are well differentiated, and 30% are 
poorly differentiated. The overall cure rate with adequate gastric resection and 
lymphadenectomy is 95%. In some Japanese centers, 50% of the gastric cancers 
treated are early gastric cancer. In the United States, less than 20% of resected 
gastric adenocarcinomas are early gastric cancer. Small intramucosal lesions can 
be treated with EMR.  
 
Stomach cancer or gastric cancer, is when cancer develops from the lining of the 
stomach.
[1]
 Early symptoms may include: heartburn, upper abdominal pain, nausea, 
and loss of appetite. Later symptoms may include: weight loss, yellow skin, 
vomiting, difficulty swallowing, and blood in the stool among others.
[2]
 The cancer 
may spread from the stomach to other parts of the body, particularly the liver, 
lungs, bones, lining of the abdomen and lymph nodes.
[3]
 
 
The most common cause is infection by the bacteria Helicobacter pylori, which 
accounts for more than 60% of cases.
[4][5]
 Certain type of H. pylori have greater 
risks than others. Other common causes include eating pickled vegetables, and 
smoking. About 10% of cases run in families and between 1% and 3% of cases are 
due to genetic syndromes inherited from a person's parents such as hereditary 
diffuse gastric cancer. Most cases of stomach cancers are gastric carcinomas. This 
type can be divided into a number of subtypes. Lymphomas and mesenchymal 
tumors may also develop within the stomach.  
 
Most of the time, stomach cancer develops through a number of stages over a 
number of years.
[5]
 Diagnosis is usually by biopsy done during endoscopy. This is 
than followed by medical imaging to determine if the disease has spread to other 
parts of the body.
[2]
 At least Japan and South Korea, two countries that have high 
rates of disease, screen for stomach cancer.
[5]
 
A Mediterranean diet lowers the risk of cancer as does the stopping of smoking. 
There is tentative evidence that treating H. pylori decreases the future risk.
[5][6]
 If 
cancer is treated early many cases can be cured.
[5]
 Treatments may include some 
combination of: surgery, chemotherapy, radiation therapy and targeted therapy.
[2]
 If 
treated late palliative care may be advised.
[5]
 Outcomes are often poor with a less 
than 10% 5-year survival rate globally. This is largely because most people with 
the condition present with advanced disease.
[7]
 In the United States 5-year survival 
is 28%
[8]
 while in South Korea it is over 65% partly due to screening efforts.
[5] 
 
 
 
 
 
 
 
 
 
 
 
 
PRECURSOR LESIONS OF CARCINOMA STOMACH 
 CHRONIC ATROPHIC GASTRITIS 
 ADENOMATOUS GASTRIC POLYPS 
 INTESTINAL METAPLASIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES OF THE STUDY  
  
  
 
1.  To study the prevalence of carcinoma stomach as occurring in Government 
Rajaji Hospital, Madurai. 
 
2. To study the clinical presentation including the anatomic site of occurrence and 
Histological type.  
 
3. To study the association of risk factors  
 
4. To study the surgical modalities of treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE  
  
Stomach cancer is the fourth most common cancer diagnosed and the second most 
frequent cause of cancer death worldwide (1–2). Although stomach cancer rates 
are lower in the United States than worldwide generally, substantial numbers are 
affected. The American Cancer Society estimated that 21,500 people in the United 
States (13,190 men and 8,310 women) would be diagnosed with stomach cancer 
and 10,880 would die from the disease during 2008 (3). Incidence and mortality 
rates for stomach cancer in the United States have decreased steadily for many 
years (4–6). 
 
Stomach cancer may be classified into intestinal and diffuse types based on 
histopathology, as initially described by Lauren (7). The two biological entities are 
different with regards to epidemiology, etiology, pathogenesis, and tumor 
behavior. The diffuse type occurs in relatively younger individuals and has a 
poorer prognosis compared with the intestinal type (8). Using the Surveillance, 
Epidemiology, and End Results (SEER) data from 1973 to 2000, Henson et al 
reported that rates for the intestinal type decreased about 50%, while rates for the 
diffuse or signet type rose more than 400% (9). 
Stomach cancers also can be classified by subsite within the stomach: cardia, 
fundus, body, distal (antrum and pylorus), and lesser or greater curvature. Some 
studies have shown that there has been a striking increase in gastric cardia cancer 
in the United States since the 1970s, although the incidence of stomach cancer as a 
whole has decreased (10–11). Using the SEER-9 data from 1974–1976 to 1992–
1994, Devesa et al (11) reported that the age-adjusted (1970 U.S. standard) 
incidence rates of gastric cardia cancer increased in both white males (from 2.1 to 
3.3 per 100,000 person-years) and black males (from 1.0 to1.9 per 100,000 person-
years). However, a more recent report using SEER-11 data for cases diagnosed 
during 1992–1998 found that gastric cardia rates did not significantly increase 
during that time period among any ethnic or gender group (12). 
 
Expanding on previous studies and adding cancer cases diagnosed through 2005, 
we used SEER data to analyze stomach carcinoma incidence patterns by histologic 
type, anatomic site, race, gender, and age.  
 
 
 
 
 
Gross Morphology and Histologic Subtypes 
 
There are four gross forms of gastric cancer: polypoid, fungating, ulcerative, and 
scirrhous. In the first two, the bulk of the tumor mass is intraluminal. 
Polypoid tumors are not ulcerated; fungating tumors are elevated intraluminally, 
but also ulcerated. In the latter two gross subtypes, the bulk of the tumor 
mass is in the wall of the stomach.  
 
Ulcerative tumors are self-descriptive; scirrhous tumors infiltrate the entire 
thickness of the stomach and cover a very large surface area. Scirrhous tumors 
(linitis plastica) have a particularly poor prognosis, and commonly involve the 
entire stomach. Although these latter lesions may be technically resectable with 
total gastrectomy, it is common for both the esophageal and duodenal margins of 
resection to show microscopic evidence of tumor infiltration. Death from recurrent 
disease within 6 months is common. 
 
The location of the primary tumor in the stomach is important in planning the 
operation. Several decades ago, the large majority of gastric cancers were in 
the distal stomach. Recently, there has been a proximal migration of tumors, so 
that currently, the distribution is closer to 40% distal, 30% middle, and 
30% proximal. 
 
 
Histology 
The most important prognostic indicators in gastric cancer are both histologic: 
lymph node involvement and depth of tumor invasion. Tumor grade (degree 
of differentiation: well, moderately, or poorly) is also important prognostically. 
There are several histologic classifications of gastric cancer. The World Health 
Organization recognizes several histologic types (Table 26-18). The Japanese 
classification is similar but more detailed. The commonly used Lauren 
classification separates gastric cancers into intestinal type (53%), diffuse type 
(33%), and unclassified (14%). The intestinal type is associated with chronic 
atrophic gastritis, severe intestinal metaplasia, and dysplasia, and tends to be 
less aggressive than the diffuse type. The diffuse type of gastric cancer is more 
likely to be poorly differentiated and is associated with younger patients 
and proximal tumors. The Ming classification also is useful and easy to remember, 
with only two types—expanding (67%) and infiltrative (33%). 
 
 
 
  
 
Table 26-18 World Health Organization Histologic Typing of Gastric Cancer 
Adenocarcinoma 
Papillary adenocarcinoma 
Tubular adenocarcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma 
Adenosquamous carcinoma 
Squamous cell carcinoma 
Small cell carcinoma 
Undifferentiated carcinoma 
Others 
Source: Reproduced with permission from Ming S-C, Hirota T: Malignant 
epithelial tumors of the stomach, in Ming S-C, Goldman H (eds): Pathology of the 
Gastrointestinal Tract, 2nd ed. Baltimore: Williams & Wilkins, 1998. 
 
 
 
  
 
Pathologic Staging 
 
Ultimately, prognosis is related to pathologic stage. The most widespread system 
for staging of gastric cancer is the tumor-node-metastasis (TNM) staging 
system based on depth of tumor invasion, extent of lymph node metastases, and 
presence of distant metastases. This system was developed by the 
American Joint Committee on Cancer and the International Union Against Cancer, 
and has undergone several modifications since it was originally conceived 
 
 
 
 
 
 
 
 
 
  
 
Stage grouping 
 
Stage T N M 
 
0 Tis N0 M0 
IA T1 N0 M0 
IB T1 N1 M0 
T2 N0 M0 
II T1 N2 M0 
T2 N1 M0 
T3 N0 M0 
IIIA T2 N2 M0 
T3 N1 M0 
T4 N0 M0 
IIIB T3 N2 M0 
IV T4 N1–3 M0 
T1–3 N3 M0 
Any T Any N M1 
Source: Used with the permission of the American Joint Committee on Cancer 
(AJCC), Chicago, Illinois. The original source for this material is the AJCC 
Cancer Staging Manual, Sixth Edition (2002) published by Springer Science and 
Business Media LLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLASSIFICATIONS 
1. LAURENS: 
2. JAPANESE 
3. BORMANNS 
4. MINGS 
5. WHO 
6. SIEWERT FOR PROXIMAL GASTRIC CARCINOMA 
7. MORPHOVOLUMETRIC 
8. MORSON & DAWSON 
9. KAJITANI 
 
 
 
 
 
 
 
 
 
 
CLINICAL MANIFESTATIONS 
 
Symptoms include  
 abdominal pain,  
 nausea and or or vomiting,  
 weight loss,  
 anorexia,  
 jaundice,  
 early satiety,  
 dysphagia,  
 malena and others. 
 
 
 
 
 
 
 
 
 
Signs include  
 anaemia,  
 icterus, 
 dehydration,  
 ascites,  
 visible gastric peristalsis &  
 mass abdomen 
 
 
 
 
 
 
 
 
 
 
 
 
 
LYMPH NODE GROUPS 
 
GROUP 1 – PERIGASTRIC NODES 
GROUP 2 – ALONG THE ROOT OF MAJOR VESSELS 
GROUP 3 – AT THE ROOT OF SUPERIOR MESENTERIC ARTERY & 
HEPATODUODENAL LIGAMENT 
GROUP 4 –DISTANT LYMPH NODES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DIFFERENTIAL DIAGNOSIS 
 
 ACID PEPTIC DISEASE 
 PYLORIC STENOSIS WITH GASTRIC OUTLET OBSTRUCTION 
 GASTRITIS 
 PANCREATIC MASS – CARCINOMA 
 TRANSVERSE COLON MASS – CARCINOMA 
 ADVANCED FIXED STOMACH MASS MAY MIMIC 
RTROPERITONEAL OR NODAL MASS 
 
 
 
 
 
 
 
 
 
 
LEATHER BOTTLE STOMACH 
- ALSO CALLED LINITIS PLASTICA 
- AN AGGRESSIVE DIFFUSE TYPE OF CARCINOMA STOMACH 
- MOTHER OF PEARL APPEARANCE 
- TYPE 4 GASTRIC CARCINOMA 
- POORLY DIFFERENTIATED TYPE LACKING GLANDULAR 
FORMATION 
- SPREADS SUBMUCOSALLY 
- COMMON IN YOUNG, FEMALES, FAMILIAL, BLOOD GROUP A. 
- SMALL SIZED STOMACH IN BARIUM MEAL STUDY 
- TOTAL GASTRECTOMY WITH ESOPHAGO JEJUNAL 
ANASTAMOSIS. 
 
 
 
 
 
 
 
 
BARIUM MEAL FINDINGS INN CARCINOMA STOMACH 
 
1. IRREGULAR FILLING DEFECT 
2. LOSS OF RUGOSITY 
3. DELAYED EMPTYING 
4. DILATATION OF STOMACH IN CARCINOMA PYLORUS 
5. DECREASED STOMACH CAPACITY IN LINITIS PLASTICA 
6. MARGIN OF THE LESION PROJECTS OUTWARDS FROM THE 
ULCER / LESION INTO THE GASTRIC LUMEN – CARMANNS 
MENISCUS SIGN. 
 
 
 
 
 
 
 
 
 
 
DIAGNOSTIC EVALUATION 
Distinguishing between peptic ulcer and gastric cancer on clinical grounds alone is 
usually impossible. Patients over the age of 45 years old who have newonset 
dyspepsia, as well as all patients with dyspepsia and alarm symptoms (weight loss, 
recurrent vomiting, dysphagia, evidence of bleeding, or anemia) 
or with a family history of gastric cancer should have prompt upper endoscopy and 
biopsy if a mucosal lesion is noted. Essentially, all patients in whom 
gastric cancer is part of the differential diagnosis should have endoscopy and 
biopsy. If suspicion for cancer is high and the biopsy is negative, the patient 
should be re-endoscoped and more aggressively biopsied. In some patients with 
gastric tumors, upper GI series can be helpful in planning treatment. 
Although a good double-contrast barium upper GI examination is sensitive for 
gastric tumors (up to 75% sensitive), in most centers, endoscopy has 
become the gold standard for the diagnosis of gastric malignancy. 
Preoperative staging of gastric cancer is best accomplished with abdominal/pelvic 
CT scanning with IV and oral contrast. MRI is probably comparable. The 
best way to stage the tumor locally is via EUS, which gives fairly accurate (80%) 
information about the depth of tumor penetration into the gastric wall, 
and can usually show enlarged (>5 mm) perigastric and celiac lymph nodes. In 
some centers, if the tumor is transmural (T3) or involves lymph nodes 
(enlarged nodes can usually be needled under ultrasound guidance), preoperative 
(neoadjuvant) chemotherapy is given. However, there are limitations to 
tumor staging with EUS. It largely is operator dependent and may underestimate 
lymph node involvement because normal-sized nodes (<5 mm) can 
harbor metastases. EUS is most accurate in distinguishing early gastric cancer (T1) 
from more advanced tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PREOPERATIVE PREPARATION  
 
- CORRECTION OF ANAEMIA, NUTRITION, FLUID & 
ELECTROLYTE. 
- CARDIAC, RESPIRATORY & RENAL STATUS ASSESSMENT 
- STOMACH WASH USING NORMAL SALINE 
- PROPHYLACTIC ANTIBIOTIC AS ACHLORHYDRIA IN GASTRIC 
LUMEN ALLOWS COLONISATION OF STREPTOCOCCUS FECALIS, 
E.COLI, BACTEROIDES, STAPHYLOCOCCUS ALBUS. 
- BLOOD / FFP MAY BE NEEDED PREOPERATIVELY AND FOR 
SURGERY. 
 
 
 
 
 
 
 
 
 
Staging Laparoscopy and Peritoneal Cytology 
 
To some extent, the usefulness of these modalities depends on the individual 
patient's situation as well as the treatment philosophy of the cancer team. 
The fundamental question is "will it make a difference to this patient's 
management?" Patients with gastric cancer who undergo R0 resection (i.e., no 
gross residual disease) and are found to have positive peritoneal cytology (no gross 
carcinomatosis) have a much worse prognosis than the cytology negative 
group (median survival 14.8 months vs. 98.5 months).96 It is controversial how 
much this information adds prognostically to that of pathologic staging 
(TNM). Whether this poor prognosis can be improved postresection with 
aggressive adjuvant treatment (systemic, or local intraperitoneal hyperthermic 
chemotherapy) is unknown. Unfortunately, it is also unclear how much these 
patients benefit from gastric resection. Currently peritoneal cytology 
information is unlikely to change the treatment of patients with gastric cancer, and 
most patients without detectable distant metastases will have (and 
should have) gastric resection regardless of the peritoneal cytology results. A quick 
laparoscopic examination can occasionally reveal small peritoneal 
implants or liver metastases that were not detected on preoperative imaging studies 
and, in some patients (e.g., high risk for surgery or impressive 
carcinomatosis), this will change the operative plan and avoid a major but futile 
surgical procedure. Laparoscopy may be most useful in patients with 
proximal tumors or with adenopathy on spiral CT scan.97 An extensive 
laparoscopic staging procedure, although quite accurate, has not been widely 
adopted.  
 
 
FIG: CARCINOMA STOMACH – BORMANN CLASSIFICATION 
 
 
 
 
 
 
 
 
 
  
 
HISTOGRAPHIC PICTURES OF Adenocarcinoma.   
 
 
 
 
 
 
 
 
 
 
 
Table 1- Lauren’s Classification System   
INTESTINAL DIFFFUSE 
Environmental Familial 
Gastric Atrophy, metaplasia Blood group A 
Men>Women Women>men 
Increasing incidence with age Younger age group 
Gland formation Poorly differentiated, signet ring cells 
Hematogenous spread Transmural/lymphatic spread 
Microsatellite instability, APC gene Decrease E-cadherin mutations 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 - Genetic Abnormalities in Gastric Cancer 
 
ABNORMALITIES GENE APPROXIMATE 
FREQUENCY 
Deletion/suppression P53 
FHIT 
APC 
DCC 
E- cadherin 
60-70 
60 
50 
50 
<5 
Amplification/overexpression COX 
HGF/SF 
VEGF 
c-met 
AIB -1 
Catenin 
k- sam 
Ras 
c-erb B2 
70 
60 
50 
45 
40 
25 
20 
10-15 
5-7 
Microsatellite instability  25-40 
DNA aneuploidy  60-75 
 
  
 
Fig.3 The role of Helicobacter Pylori  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 Fig .4 T Stage defined by depth of penetration into gastric wall 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig 5 Lymph node station numbers as defined by Japanese Cancer Association  
  
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 Table 6 - Grouping of Regional Lymph Nodes (Groups 1-3) by Location of 
Primary Tumor According to the Japanese Classification of Gastric Carcinoma  
   
LOCATION OF PRIAMRY TUMOUR IN  
THE STOMACH  
 
 
LYMPH 
NODE 
STATION(No 
 
DESCRIPTION  
 
 
UPPER 
THIRD 
 
MIDDLE 
THIRD 
 
LOWER 
THIRD 
1 Right 
paracardial  
 
1 1 2 
2 Left paracardial  
 
1 3 M 
3 Lesser 
curvature 
1 1 1 
4sa Short gastric  
 
1 3 M 
4sb Left 
gastroepiploic 
1 1 3 
4d Right 
gastroepiploic 
2 1 1 
5 Suprapyloric  
 
3 1 1 
6 Infrapyloric  
 
3 1 1 
7 Left gastric 
artery  
 
2 2 2 
8a Anterior comm. 
hepatic  
 
2 2 2 
8p Posterior 
comm. hepatic  
 
3 3 3 
9 Celiac artery  
 
2 2 2 
10 Splenic hilum  
 
2 3 M 
11p Proximal 
splenic  
 
2 2 2 
11d Distal splenic  
 
2 3 M 
12a Left 
hepatoduodenal  
 
3 2 2 
12b,p Posterior 
hepatoduodenal  
 
3 3 3 
13 Retropancreatic  
 
M 3 3 
14v Superior 
mesenteric vein  
M 3 2 
 14a Superior 
mesenteric 
artery  
 
M M M 
15 Middle colic  
 
M M M 
16a1 Aortic hiatus  
 
3 M M 
16a2,b1 Para-aortic, 
middle  
 
M 3 3 
16b2 Para-aortic, 
caudal  
 
M M M 
 
M, lymph nodes regarded as distant metastasis 
 
 
  
  
  
  
  
 BIRMINGHAM STAGING 
 
1- CONFINED TO MUCOSA / MUSCULARIS PROPRIA 
2- MUSCULARIS / SEROSAL INVOLVEMENT 
3- NODAL SPREAD 
4a- RESIDUAL DISEASE 
4b- METASTATIC DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spread of carcinoma of the stomach  
 
No better example of the various modes by which carcinoma spreads can be given 
than the case of stomach cancer. It is important to note that this distant spread  is 
unusual before the disease spreads locally and distant metastases are uncommon in 
the absence of lymph node metastases. The intestinal and diffuse types of gastric 
cancer spread differently. The diffuse type spreads via the submucosal and 
subserosal lymphatic plexus and it penetrates the gastric wall at an early stage.  
 
Unlike malignancies such as breast cancer, nodal involvement does not imply 
systemic dissemination.  
 
Blood-borne metastases  
 
This occurs first to the liver and subsequently to other organs including lung and 
bone. This is uncommon in the absence of extensive nodal disease.  
 
Trans peritoneal spread  
 
This is a common mode of spread once the tumour has reached the serosa of the 
stomach and indicates incurability. Tumours can manifest anywhere in the 
peritoneal cavity and commonly give rise to ascites. Advanced peritoneal disease 
may be palpated either abdominally or rectally as a tumour ‘shelf’.   
 
The ovaries may sometimes may be the sole site of transcoelomic spread 
(Krukenberg’s tumours). Tumour may spread via the abdominal cavity to the 
umbilicus (Sister Joseph’s nodule).  25  
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT OF LOCALIZED DISEASE 
 
STAGE I DISEASE (EARLY GASTRIC CANCER) - Classification and Risk 
for Nodal Metastases 
 
The  Japanese  Research  Society  for  Gastric  Cancer  has  classified  early 
gastric  cancers  (EGC)  based  on  endoscopic  criteria  first  established  
by  the Japanese Endoscopy Society for the description of T1 tumors.  
 
The  current  classification  system  is  used  for  both  in  situ  and  invasive tumors 
and categorizes tumors based on endoscopic findings as follows:  
 
 
 
 
 
 
 
 
 
 
Figure 6 . Japanese classification system for early gastric cancer. In the combined 
superficial types, the type occupying the largest area should be described first, 
followed by the next type (e.g., IIc + III). Type 0I and Type 0IIa are distinguished 
as follows: Type 0I: The lesion has a thickness of more than twice that of the 
normal mucosa. Type 0IIa: The lesion has a thickness up to twice that of the 
normal mucosa.  
 
 
 
  
 
 
 
 
Considering the risk for lymph node metastasis is important when evaluating 
treatment options for patients with EGC. The frequency and anatomic distribution 
of nodal disease are related to the depth of tumor invasion.  10   
 
Treatment options for patients with EGC include   
 
-  Endoscopic Mucosal Resection (EMR),  
-  Limited surgical resection,  
-  Gastrectomy. 
 
 
 
 
 
 
 
 
 
 
 
Endoscopic Resection 
 
It has been demonstrated initially at numerous East Asian centers that some 
patients with early gastric cancer can be adequately treated by an EMR. Small 
tumors (<3 cm) confined to the mucosa have an extremely low chance of lymph 
node metastasis (3%), which approaches the operative mortality rate for 
gastrectomy. If the resected specimen demonstrates no ulceration, no penetration 
of the muscularis mucosae, no lymphatic invasion, and size <3 cm, then 
the risk of lymph node metastases is less than 1%. Thus, some patients with early 
gastric cancer might be better treated with the endoscopic technique. 
Currently, this should be limited to patients with tumors <2 cm in size that are 
node negative and confined to the mucosa on EUS, in the absence of other 
gastric lesions. The addition of laparoscopic lymph node sampling may be 
considered in selected patients. 
 
 
 
 
 
 
 Limited Surgical Resection  
 
Given the low rate of nodal involvement for patients with EGC, limited resection 
may be a reasonable alternative to gastrectomy for some patients with early EGC. 
There are no well-accepted pretreatment criteria for selection of patients for limited 
resection. Based on the existing pathology data, patients with small (less than 3 cm) 
intramucosal tumors and those with nonulcerated intramucosal tumors of any size 
may be candidates for EMR or limited resection. Surgical options for these patients 
may include gastrectomy with local excision.   
 
Gastrectomy  
 
Gastrectomy with lymph node dissection should be considered for patients with 
EGC who cannot be treated with EMR or limited surgical resection and/or patients 
who have intramucosal tumors with poor histologic differentiation or size greater 
than 3 cm or who have tumor penetration into the submucosa or beyond.  
 
Gastrectomy with lymph node dissection allows for adequate pathologic staging 
and local therapy for these higher-risk patients. There is no consensus on the extent 
of lymphadenectomy that should be performed as part of gastrectomy for EGC. 
Dissection of level I lymph nodes is a reasonable minimum standard at this time.   
 
STAGE II AND STAGE III DISEASE  
 
  
TREATMENT 
 
Surgical resection is the only curative treatment for gastric cancer98,99 and most 
patients with clinically resectable locoregional disease should have gastric 
resection. Obvious exceptions include patients who cannot tolerate an abdominal 
operation, and patients with overwhelming metastatic disease. 
The goal of curative surgical treatment is resection of all tumor (i.e., R0 resection). 
Thus, all margins (proximal, distal, and radial) should be negative and 
an adequate lymphadenectomy performed. Generally, the surgeon strives for a 
grossly negative margin of at least 5 cm. Some gastric tumors, particularly 
the diffuse variety, are quite infiltrative and tumor cells can extend well beyond the 
tumor mass; thus, gross margins beyond 5 cm may be desirable. 
Frozen section confirmation of negative margins is important when performing 
operation for cure, but it is less important in patients with nodal metastases 
beyond the N1 nodal basin. It should be strongly emphasized that many patients 
with positive lymph nodes are cured by adequate surgery. It should also 
be stressed that often lymph nodes that appear to be grossly involved with tumor 
turn out to be benign or reactive on pathologic examination. More than 
15 resected lymph nodes are required for adequate staging.100 Therapeutic 
nihilism should be avoided and, in the low-risk patient, an aggressive attempt 
to resect all tumor should be made. The primary tumor may be resected en bloc 
with adjacent involved organs (e.g., distal pancreas, transverse colon, or 
spleen) during the course of curative gastrectomy. Palliative gastrectomy may be 
indicated in some patients with obviously incurable disease, but most 
patients presenting with stage IV gastric cancer can be managed without major 
operation.99,101 
 
Extent of Surgery 
 
Unless required for R0 resection, total gastrectomy confers no additional survival 
benefit and may have adverse nutritional or quality-of-life consequences, and 
higher perioperative morbidity and mortality.98,99 Subtotal gastric resection 
typically entails ligation of the left and right gastric and gastroepiploic arteries at 
the origin, as well as the en bloc removal of the distal 75% of the 
stomach, including the pylorus and 2 cm of duodenum, the greater and lesser 
omentum, and all associated lymphatic tissue (Fig. 26-56). Reconstruction is 
usually by Billroth II gastrojejunostomy, but if a small gastric remnant is left 
(<20%), a Roux-en-Y reconstruction is considered. The operative mortality is 
around 2 to 5%. Radical subtotal gastrectomy is generally deemed to be an 
adequate cancer operation in most Western countries, provided that the 
contingencies stated result in tumor-free margins, >15 lymph nodes, and the 
resection of all gross tumor. In the absence of involvement by direct 
extension, the spleen and pancreatic tail are not removed. 
 
Extent of Lymphadenectomy  
 
The dialogue surrounding lymphadenectomy involves at least two important issues: 
(1) staging removal and histopathologic analysis of an adequate number of  lymph 
nodes, and (2) therapy determining if some forms of lymphadenectomy are 
therapeutic for patients with gastric cancer.  The current AJCC staging system 
(sixth edition) requires analysis of 16 or more lymph nodes to assign a pathologic N 
stage.  
 
 
 
Adjuvant Therapy  
 
The term adjuvant therapy is best used to describe additional treatment in an 
attempt to increase cure rates in patients who have already undergone a potentially 
curative resection. For gastric cancer, an R0 surgical procedure, in which all gross 
disease has been removed, the margins of resection are microscopically negative, 
and no distant metastases were found, is required before adjuvant therapy is 
considered. Resections that leave microscopic or gross residual disease are not 
adjuvant treatment, but rather therapy of known residual cancer.  
 
The term perioperative chemotherapy (or neoadjuvant chemotherapy) involves the 
use of systemic treatment before definitive, potentially curative surgery.  
 
 
 
Adjuvant Postoperative Systemic Therapy  
 
Adjuvant postoperative systemic chemotherapy has not shown a significant 
advantage over surgery alone.  
 
Postoperative Adjuvant Intraperitoneal Chemotherapy  
 
Peritoneal recurrence is a common component of the failure pattern for patients 
with gastric cancer.  
 
For gastric cancer, an increasing number of reports have been published in which 
immediate postoperative intraperitoneal therapy was given after potentially curative 
resection. However, no definitive conclusions can yet be drawn regarding the 
effectiveness of intraperitoneal postoperative chemotherapy in this setting.  
 
 
 
Immunochemotherapy  
 
Adjuvant immunostimulants  given in association with cytotoxic chemotherapy has 
been studied, however larger studies that are adequately powered would be 
necessary to definitively evaluate this approach. 
  
 
 
Perioperative (Neoadjuvant) Chemotherapy  
 
Perioperative (pre-  and postoperative) chemotherapy, also known as neoadjuvant 
chemotherapy, is an attractive concept in gastric cancer because many patients, 
particularly Western patients, have locally advanced tumors at diagnosis (T3 or T4, 
or obvious lymph node involvement).   
 
Such patients are not only at substantial risk for distant metastasis, but local extent 
of the tumor may make an R0 resection difficult.   
 
There are two goals to perioperative treatment: reduce the stage of the primary 
tumor to increase the likelihood that a R0 resection can be performed, and begin at 
an early time to treat micrometastatic disease.   
 
The right gastric artery is ligated. At this point, the duodenum is divideddistal to the 
pylorus. The stomach and omentum are then reflected cephalad. The gastro hepatic  
ligament is divided close to the liver up to the gastro esophageal junction. 
Dissection is then continued on the hepatic artery toward the celiac axis.For tumors 
of the mid-  and proximal  stomach, dissection of the lymph nodes along the splenic 
artery and splenic hilum is important.   
 This technique is not indicated for antral tumors, given the low rate of splenic hilar 
nodal metastases seen with these tumors. The stomach is then divided 5 cm 
proximal to the tumor, which dictates the extent of gastric resection.   
 
Despite the fact that the entire blood supply of the stomach has been interrupted, a 
cuff of proximal stomach invariably shows good vascularization from the feeding 
distal esophageal arcade.  
 
TREATMENT OF ADVANCED DISEASE (STAGE IV)  
 
Single-Agent Chemotherapy  
 
For most drugs, a variety of doses and schedules have been studied. In the absence 
of  comparative trials using the same agent with different doses and schedules, 
superiority of one regimen over the other cannot be assessed.   
 
 
 
 
Combination Chemotherapy  
 
  
Like other malignancies, multidrug regimens using agents that have a single-agent 
activity have been extensively studied in gastric cancer.   
 
One of the most widely used combination chemotherapy regimens in upper 
gastrointestinal tract malignancies, including gastric cancer, is the two-drug 
combination of cisplatin and fluorouracil.   
 
Other combination chemotherapy regimens include methotrexate, fluorouracil, and 
doxorubicin (FAMTX); etoposide, leucovorin, and fluorouracil combination;  
fluorouracil plus irinotecan;  docetaxel  added cisplatin fluorouracil; epirubicin-
cisplatin-fluorouracil;  irinotecan-fluorouracil-leucovorin  ;  Cisplatin Plus 
Irinotecan; Fluorouracil-Leucovorin-Oxaliplatin (FOLFOX)  
 
 
 
 
 
Targeted Therapy  
 
Bevacizumab   
 
As with other solid tumors, including colorectal cancer, breast and lung cancers, 
therapeutic agents with a specific tumor target are now entering study in gastric and 
gastroesophageal junction tumors. One of the first compounds studied was 
bevacizumab, a humanized monoclonal antibody that binds the vascular endothelial 
growth factor ligand. Bevacizumab can safely be given with cytotoxic 
chemotherapy, including in patients in whom the primary tumor was still in place.  
 
Epidermal Grow th Factor Receptor Tyrosine Kinase Inhibitors  
 
Both erlotinib and gefitinib have been studied in gastroesophageal junction and 
gastric cancers. The  bulk of the data is currently available only an abstract form.  
Cetuximab, an antibody to the epidermal growth factor receptor, is undergoing 
study as a single agent and also in combination with systemic cytotoxic 
chemotherapy.  
 
 
Long-Term Side Effects of Therapy  
 
Relatively little has been written in the oncology literature on the local effects of 
therapy for gastric cancer and its long-term implications. The presence of dumping 
syndrome is well known, with its resulting diarrhea and cramping, but vasomotor 
effects such as palpitations and diarrhea also occur either very shortly after a meal 
or 1 to 3 hours later. These symptoms probably result  from rapid transit of food 
from the stomach into the small bowel with the release of various gastrointestinal 
hormones. These symptoms can be managed by adjusting the volume of oral intake 
and other dietary manipulations. There is also a reactive hypoglycemia that can 
result from the rapid insulin release after a meal with little gastric reservoir.In 
addition to dumping, there are a number of malabsorption issues that can be 
important. B  malabsorption is well known, and many patients 12 are placed on 
monthly supplements, even if it is not clearly needed.   
 
After partial gastrectomy one can often monitor B   levels and replace 12 when 
needed. Iron and calcium absorption is improved by the gastric acid that is 
eliminated or decreased by surgery or radiation therapy, and bypassing the 
duodenum also decreases absorption. Low iron is discovered when patients develop 
an iron deficient anemia, but calcium malabsorption may not be found for many 
years when the patient develops osteopenia. Patients should be followed with dual 
energy x-ray absorptiometry scans and/or placed on calcium supplementation 
(calcium citrate is better absorbed than calcium carbonate).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODOLOGY  
 
The  tissue  for  diagnosis  was obtained by endoscopy or following surgical 
resection.  
 
Source of Data  
 
Patients presenting to Govt. Rajaji Hospital, Madurai   during the study period  and 
those found eligible were included in the study.  
Sample size: Minimum of 50 cases meeting criteria of the present study  
 
Inclusion Criteria  
 
•    Only patients with histological proven carcinoma stomach were included  
 
 
Exclusion criteria  
 
•    Patients with tumour recurrence  
 
COLLABORATING DEPARTMENTS: 
 
Departments of General surgery,  
Department of Surgical Gastroenterology, 
Department of surgical oncology, 
 
STUDY PERIOD: 12 months 
 
 
 
 
 
 
 
INVESTIGATIONS  
Routine Blood investigations like Haemoglobin%, Total Count, Differential Count, 
Bleeding Time, Clotting time.  
 
Renal parameters like Blood Urea and Serum Creatinine  
 
Liver Function Tests  
 
Serum Electrolytes  
 
Chest X-Ray  
 
Blood Grouping  
 
Special investigations like Upper Gastointestinal Endoscopy,  
 
USG Abdomen  
 
CT Scan Abdomen  
 
The cases were studied with importance given to clinical history regarding nature of 
presentation including diet history. The study of association of risk factors was also 
undertaken. Thorough clinical examination, Ultrasonography, endoscopy, CT in 
few cases and histopathologic diagnosis formed the basis of the study. The 
anatomic site of occurrence, the macroscopic type and the histopathologic type 
were studied in each case. An earnest attempt was made to study all the cases in 
detail with serial follow-up, the latter being incomplete due to non-responsive 
patients.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
ANNUAL PREVALENCE: Graph-1 
 
Gastric  carcinoma  is  a  common  cancer  with  almost  evenly  distributed 
annual prevalence.  
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SEX PREVALENCE: Table 7; Graph 2 
 
Table-7. Sex distribution among carcinoma stomach patients 
 
Gastric  cancer  is  more  common  in  males  with  56%  of  the  cases  being 
males in this study. 
 
SEX PRESENT STUDY 
CASES % 
MALE 28 56 
FEMALE 22 44 
 
 
 
 
 
  
 
 
 
 
 
AGE PREVALENCE: Table 8; Graph 3 
Table-8.  Age distribution among carcinoma stomach patients 
AGE PRESENT STUDY 
TOTAL % M F 
<30 1 2 1 0 
30-39 7 14 1 6 
56% 
44% 
% OF INCIDENCE - SEX DISTRIBUTION 
MALE FEMALE
40-49 9 18 2 7 
50-59 15 30 11 4 
60-69 12 24 8 4 
70-79 6 12 5 1 
80+ 0 0 0 0 
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SOCIOECONOMIC STATUS: Table 9; Graph 4  
 
The prevalence among the high socioeconomic group could not be studied as none 
of the patients belonged to this strata.  
 
Table 9- Income group among carcinoma stomach patients  
 
INCOME GROUP PRESENT STUDY 
CASES % 
LOW 40 80 
MIDDLE 10 20 
HIGH 0 0 
  
 
 
 
 
 
  
 
RISK FACTORS: Table 10; Graph 5.0, 5.1  
 
There are strong suggestions of the influence of environmental factors on gastric  
cancer.  The  most  common  risk  factors  associated  were  spicy  food  and mixed 
diet followed by tobacco and alcohol use.  
 
In this study 45 (90%)  patients consumed mixed diet and the rest  were  
vegetarians.  The  non  vegetarians  took  meat/fish  approx.  thrice  every week. 
All patients in the study group frequently and regularly consumed green leafy 
vegetables. 
LOW 
80% 
MIDDLE 
20% 
% OF INCIDENCE -SOCIO ECONOMIC 
DISTRIBUTION 
 Fruit consumption was frequent  only in 40 (80%) of the  cases. 
 
Smoked  foods  though  a  common  risk  factor  in  many  countries  was 
consumed only by 15 (30%) of the patients and even in theses patients the intake 
was not frequent. Majority of the patients, 40 (80%) reported to the use of high 
spicy diet in everyday food. 
 
Tobacco smoking in the form of cigarette and beedi smoking was seen in 22 (44%) 
patients, all being males. Five females and three males reported to  frequent  use  
of  betelnut  which  has  been  shown  to  a  risk  factor  in  the development of 
gastric cancer.  
 
Alcohol consumption was seen in 22 (44%) of the patients, all males, who 
consumed it regularly and for a period of more than ten years.  
  
 
 
 
 
Table 10 - Comparision of risk factors between males and females 
 
RISK FACTORS TOTAL MALES FEMALES 
CASES % CASES % CASES % 
MIXED DIET 45 90 26 92.8 19 86.3 
VEGETARIAN DIET 5 10 2 7.2 3 13.7 
GREEN LEAFY  40 80 25 89.2 15 68.1 
FRUITS 40 80 24 85.7 16 72.7 
HIGH SALT INTAKE 32 64 20 71.4 12 54.5 
SMOKED FOODS 15 30 10 35.7 5 22.7 
SPICY 40 80 25 89.2 15 68.1 
SMOKING 22 44 22 78.5 0 0 
ALCOHOLISM 22 44 22 78.5 0 0 
BETEL NUTS 8 16 3 10.7 5 22.7 
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BLOOD GROUP: Table 11; Graph 6  
 
Blood group A showed the highest association with gastric cancer patients with 23 
(46%) cases followed by blood group O and B.  
  
Table 11 - Blood group distribution in carcinoma stomach patients 
 
STUDY BLOOD GROUP 
A B O AB 
PRESENT 
STUDY 
23 (46%) 9 (18%) 12 (24%) 6 (12%) 
 
 
  
 
 
 
 
 
SYMPTOMS: Table 12, Graph 7  
 
Anorexia was the most common symptom in patients and was reported in 42 (84%) 
of the patients. The next most common symptom was nausea and vomiting 
reflecting the high prevalence of distal tumours. 36(72%) reported weight >10% of 
body weight.   
 
46% 
18% 
24% 
12% 
% OF INCIDENCE WITH DIFFERENT BLOOD 
GROUPS 
A
B
O
AB
Proximal tumours involving the gastooesophageal junction had dysphagia as the 
predominant symptom. Only one patient in this study presented with jaundice and 
none of the patients had supraclavicular lymphadenopathy at presentation. One 
patient presented with features of  peritonitis and was found to have a growth in the 
body of the stomach which had perforated.  
 
Early satiety was reported in 25 (50%) of  the patients which is characteristic of 
tumours involving the stomach wall diffusely.  
 
Symptom analysis among the two sexes revealed that nausea, vomiting and weight 
loss were the most common symptoms followed by pain abdomen in females. The 
most common symptoms in males were anorexia, abdominal pain followed by 
nausea and vomiting.  
 
 
 
 
 
 
 
Table 12-Symptom analysis in patients of carcinoma stomach  
 
SYMPTOMS PRESENT STUDY MALES (28) FEMALES (22) 
CASES % CASES % CASES % 
ABDOMINAL 
PAIN 
40 80 23 82.1 17 77.2 
NAUSEA & 
VOMITING 
33 66 18 64.2 15 68.1 
WEIGHT 
LOSS 
36 72 20 71.4 16 72.7 
ANOREXIA 42 84 22 78.5 20 90.9 
EARLY 
SATIETY  
25 50 15 53.5 10 45.4 
JAUNDICE 1 2 1 3.5 0 0 
DYSPHAGIA 5 10 2 7.1 3 10.7 
MALENA 10 20 5 17.8 5 17.8 
 
 
 
 
  
 
SIGNS: Table 13, Graph 8  
 
Overall, anemia was the most common sign in 35 (70%) of the cases followed by 
dehydration and ascites.   
 
Visible gastric peristalsis the characteristic sign of gastric cancer was seen only in 7 
(14%) of the cases. Gastric cancer presented as mass abdomen in 17 (34%) cases.  
 
In females, anemia and ascites were the most common symptoms. None of the 
females in this study had visible gastric peristalsis which was seen in 7 (25%) of 
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males.  
 
Presentation with mass abdomen was commoner in females 10 (45.4%) than in 
males 7 (25%).   
 
Ascites at presentation suggesting the advanced stage of the disease was more 
common in females compared to males. 
 
 
Table 13 - Analysis of signs in gastric cancer patients  
 
SIGNS TOTAL 
CASES 
% MALES FEMALES 
CASES % CASES % 
ANAEMIA 35 70 21 75 14 63.6 
ICTERUS 1 2 1 3.5 0 0 
DEHYDRATION 30 60 18 64.2 12 54.5 
ASCITIS 28 56 17 60.7 11 50 
VGP 7 14 7 25 0 0 
MASS 
ABDOMEN 
17 34 7 25 10 45.4 
.  
  
  
SUBSITES: Table 14; Graph 9  
 
The antrum was the most common site of affliction accounting for 38 (76%) of all 
subsites. This was also similar in both the sexes with 20 males and 18 females. 
Oesophagogastric tumours accounted for  9 (18)% of the cases and were similar in 
both the sexes. None of the females in this study had cancers of the body and 
proximal stomach.  
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Table 14- Sub site specific trends in carcinoma stomach  
 
SUBSITES TOTAL MALES FEMALES 
CASES % CASES % CASES % 
OG 
JUNCTION 
9 18 5 17.8 4 18.1 
PROXIMAL 
STOMACH 
1 2 1 3.5 0 0 
BODY 2 4 2 7.1 0 0 
ANTRUM 38 76 20 71.4 18 81.8 
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MACROSCOPY: Table 15  
 
The predominant macroscopic subtype was Borrmann type II with 24 (48%) 
followed by types III and IV. In males the predominant type was Borrmann type II 
where as in females it was type IV. Females had a higher percentage of locally 
advanced lesions. There were no Bormann type I lesion in females in this study. 
 
Table 15- Comparison of the macroscopic type in both sexes  
 
BORMANN 
TYPE 
TOTAL MALES FEMALES 
CASES % CASES % CASES % 
I 2 4 2 7.1 0 0 
II 24 48 16 57.1 8 36.3 
III 10 20 5 17.8 5 22.7 
IV 14 28 5 17.8 9 40.9 
 
 
 
SITE AND SYMPTOMS: Table 16; Graph 10  
 
Antral lesions presented predominantly with nausea/vomiting, weight loss, anorexia 
and pain abdomen. 50% of the antral growth patients also reported early satiety. 
 
Oesophagogastric tumours had dysphagia as the predominant symptom along with 
weight loss and anorexia reflecting the aggressive nature of such tumours. Similarly 
these entire lesions also had dysphagia as a symptom. Malena was more common in 
lesion of the body followed by the antrum.   
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SYMPTOMS TOTAL 
CASES 
SITE OF TUMOR 
ANTRUM 
(38) 
PROXIMAL 
STOMACH 
(1) 
BODY (2) OG 
JUNCTION 
(9) 
CASES % CASES % CASES % CASES % 
ABDOMINAL 
PAIN 
40 32 84.2 1 100 1 50 6 66.6 
NAUSEA / 
VOMITING 
33 30 78.9 0 0 0 0 3 33.3 
WEIGHT 
LOSS 
36 31 81.5 0 0 0 0 5 55.5 
ANOREXIA 42 34 89.4 1 100 2 100 5 55.5 
EARLY 
SATIETY 
25 19 50 0 0 1 50 5 55.5 
JAUNDICE 1 1 2.6 0 0 0 0 0 0 
DYSPHAGIA 5 1 2.6 0 0 0 0 4 44.4 
MALENA 10 6 15.7 1 100 2 100 1 11.1 
 
 
 
MACROSCOPY AND SYMPTOMS: Table 17; Graph 11  
 
Borrmann type I lesion patients experienced pain abdomen and vomiting in 100% 
of cases. All Borrmann type II lesion patients had symptoms of nausea/vomiting, 
weight loss and anorexia. Type II and III lesion patients had early satiety in 75% 
and 50% respectively. 
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SYMPTOMS TOTAL 
CASES 
BORMANN TYPES 
I (2) II (24) III (10) IV (14) 
CASE
S 
% CASE
S 
% CASE
S 
% CASE
S 
% 
ABDOMINA
L PAIN 
40 2 10
0 
20 83.
3 
8 8
0 
10 71.
4 
NAUSEA / 
VOMITING 
33 2 10
0 
24 100 2 2
0 
5 35.
7 
WEIGHT 
LOSS 
36 1 50 24 100 6 6
0 
5 35.
7 
ANOREXIA 42 1 50 24 100 7 7
0 
8 57.
1 
EARLY 
SATIETY 
25 1 50 18 75 5 5
0 
1 7.1 
JAUNDICE 1 0 0 1 4.1 0 0 0 0 
DYSPHAGI
A 
5 0 0 2 8.3 1 1
0 
2 14.
2 
MALENA 10 1 50 4 16.
6 
2 2
0 
3 21.
4 
 
 
 
SITE AND SIGNS: Table 18, Graph 12  
 
All cases of proximal tumours had anaemia at presentation. Tumours of the body 
had ascites at the time of presentation. All the cases with visible gastric peristalsis 
were antral growths, however only 18.4% of antral growths had visible peristalsis.   
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MACROSCOPY AND SIGNS: Table 19; Graph 13  
 
Majority  of type  II and type III lesions presented with anemia.  Borrmann type II, 
III  and IV lesions were more often associated with ascites than type I lesions. Type 
II and Type III lesions accounted for the majority of cases of mass abdomen.   
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HISTOPATHOLOGY: Table 20, Table 21  
 
Majority of the cases were well differentiated adenocarcinoma. Females had a 
higher percentage of poorly differentiated tumours.  
Table 20- Comparison of histopathology  
HISTOLOGY PRESENT STUDY 
DIFFERENTIATION TOTAL 
CASES 
% MALES % FEMALES % 
WELL 30 60 20 71.4 10 45.4 
MODERATELY 12 24 6 21.4 6 27.2 
POOR 8 16 2 7.1 6 27.2 
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Antral tumours were predominantly well differentiated and oesophageal had high 
percentage of poorly differentiated tumours.  
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Table 21- Comparision of histology with the site of the tumour  
HISTOLOGY PRESENT STUDY 
DIFFERENTIATION TOTAL ANTRUM 
(38) 
BODY 
(1) 
PROXIMAL 
(2) 
 OG 
JUNCTION 
(9) 
WELL 30 30 0 0 0 
MODERATELY 12 8 1 2 1 
POOR 8 0 0 0 8 
UNDIFFERENTIATED 0 0 0 0 0 
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DISCUSSION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study was undertaken to study the prevalence of gastric cancer as occurring in 
Government Rajaji Hospital, Madurai which is a tertiary care centre with a large 
input of cases from Madurai and its surrounding districts.  
 
The study had certain drawbacks. The association of H. Pylori with gastric 
carcinoma was not studied. Since histopathological confirmation was an inclusion 
criteria for the study, many  suspected cases were not included for lack of definite 
tissue diagnosis.  
 
Although CT abdomen is recommended for the staging of the disease, it was not 
performed in most of the cases due to financial constraints. Many cases were 
referred to the regional cancer institute for further treatment.  
 
Observations   were made in this study with M:F ratio of 3:1. These observations 
are comparable to   similar studies in India.   
 
 
 
 
Table 21. Sex distribution among carcinoma stomach patients 
SEX GAJALAKSHMI ET 
AL 1995 
SUMATHI ET AL 
2009 
PRESENT STUDY 
CASES % CASES % CASES % 
MALE 287 73.9 64 71.9 28 56 
FEMALE 101 26.1 25 28.1 22 44 
 
In this study maximum no of cases was seen after the age of 45 years. In this study 
the youngest patient was aged 29 and the oldest 78.  
 
Table 22.  Age distribution among carcinoma stomach patients  
 
AGE GAJALAKSHMI C 
K ET AL 1996 
SEN ET AL 2002 PRESENT STUDY 
CASES % CASES % CASES % 
<30 2 0.5 0 0.1 1 2 
30-39 30 7.7 7 0.5 7 14 
40-49 64 16.5 1 2.2 9 18 
50-59 84 21.6 20 7.2 15 30 
60-69 124 32 53 19.2 12 24 
70-79 68 17.5 77 28.0 6 12 
80+ 16 4.1 120 43.4 0 0 
 
As the study was conducted in a Government Hospital majority of the cases 
belonged to the low socioeconomic status accounting for 75%   of the cases. The 
scenario is similar across India where majority of the population belong to the low 
socioeconomic group further contributing evidence of dietary role of carcinogens. 
Studies at Chennai and other parts of the country have shown consistent correlation 
between the lower socioeconomic group and higher prevalence of gastric cancer.  
 
Table 23- Socioeconomic groups among gastric cancer patients 
 
SOCIOECONOMIC 
STATUS 
GAJALAKSHMI 
ET AL 1995 
SUMATHI ET AL 
2009 
PRESENT STUDY 
CASES % CASES % CASES % 
LOW 301 77.5 70 78.6 40 80 
MIDDLE 87 22.5 19 21.4 10 20 
HIGH 0 0 0 0 0 0 
 
The association of blood group A is well known and the findings were compared 
with other  studies. 
 
STUDY BLOOD GROUP 
A (%) B (%) O (%) AB (%) 
KAMLESH 
GULERIA ET 
AL, PUNJAB 
1 (12.5) 5 (62.5) 2 (25) 0 (0) 
JOSE ET AL, 
KERALA 
26 (37.1) 14 (20) 23 (32.85) 7 (10) 
PRESENT 
STUDY 
23 (46) 9 (18) 12 (24) 6 (12) 
  
 
 
Gastric cancer is known to be associated with several environmental risk factors of 
which diet has an important role. The association of diet has been studied in many 
studies and consistent results obtained all over. The findings of this study were 
compared with Sumathi et al. Majority of the patients were non vegetarians in both 
the studies.   
 The association of tobacco use and alcohol has been studied. In this study 22(44%) 
of the patients reported to the use of smoking for a significant periodic compared to 
40.5 patients in study by Sumathi et al. Betelnut chewing seen more in females was 
seen in 16% of the patients compared to 10.2% in the other study.  
 
Table 25- Comparision of risk factors between males and females 
 
FACTORS SUMATHI ET AL PRESENT STUDY 
CASES  % CASES % 
MIXED DIET 89 100 45 90 
VEGETARIAN 
DIET 
0 0 5 10 
GREEN 
LEAFY VEG 
58 65.2 40 80 
FRUITS 39 43.8 40 80 
HIGH SALT 
INTAKE 
0 0 32 64 
SMOKED 0 0 15 30 
FOODS 
SPICY FOODS 0 0 40 80 
SMOKING 36 40.5 22 44 
ALCOHOL 32 35.9 22 44 
BETEL NUT 9 10.2 8 16 
 
Abdominal pain was major symptom reported in 40(80%) of the cases compared to  
56.6% in a study by Safaee et al. Weight  loss was seen in 36(72%) of cases 
compared to 57.7 cases. These findings suggest that patients in our set up present in 
an early stage of the disease with both local and regional spread. The percentage of 
patients presenting with malaena was comparable in both groups.   
 
 
 
 
 
 
 
 
 
Table 26 Symptom analysis in patients of carcinoma stomach 
SYMPTOMS SAFEE ET AL 2009 PRESENT STUDY 
CASES % CASES % 
ABDOMINAL 
PAIN 
425 56.6 40 80 
NAUSEA & 
VOMITING 
324 43.2 33 66 
WEIGHT 
LOSS 
434 57.7 36 72 
ANOREXIA - - 42 84 
EARLY 
SATIETY  
263 31.5 25 50 
JAUNDICE - - 1 2 
DYSPHAGIA 263 31.5 5 10 
MALENA 144 19.1 10 20 
 
The west has noted a paradigm shift in site of gastric cancer tumours with a steady 
increase in tumours of the cardium and proximal tumours and a decline in distal 
tumours. In this study distal tumours continued to be the most common site of 
affliction with 38(76%) cases and only 9 cases(18%) of proximal tumours. Cherian 
et al 8   studying a 16 year trend of gastric cancer at Chennai also had similar 
findings.  
 
Table 27 Sub site specific trends in carcinoma stomach 
 
SUB SITE CHERIAN ET AL PRESENT STUDY 
CASES % CASES % 
OG 
JUNCTION 
65 3.78 9 18 
PROXIMAL 
STOMACH 
97 5.64 1 2 
BODY 400 23.27 2 4 
ANTRUM 1157 67.31 38 76 
 
In this study majority of the tumours were well differentiated. Moderately and 
poorly differentiated were equally differentiated. In the study by Safee et al poorly 
differentiated tumours were more common. 
 
 
 
Table 28 Comparision of histology according to Broder's classification 
 
HISTOLOGY SAFEE ET AL PRESENT STUDY 
DIFFERENTIATION CASES % CASES % 
WELL 113 23 30 60 
MODERATELY 142 30.1 12 24 
POOR 203 43 8 16 
UNDIFFERENTIATED 14 3 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION  
 
This study was undertaken to study the prevalence of gastric cancer as occurring in 
Government Rajaji Hospital, Madurai which is a tertiary care centre with a large 
input of cases from Madurai and its surrounding districts.  
 
In this study gastric cancer was more prevalent in males.   
 
Majority of the patients belonged to the lower socioeconomic strata and had 
association of risk factors. Blood group A was the prevalent blood group.  
 
The disease was more prevalent in patients above the age of 45 with the oldest 
being 78. Majority presented in the advanced stage of the disease although there 
were few cases which presented in the early gastric carcinoma stage.   
 
The pylorus remained the most common site of affliction in contrast to western 
countries which have showed a consistent shift towards proximal tumours. The 
major percentage of the tumours was well differentiated.   
 
The findings of this study are comparable to other similar studies in India and 
proximal gastric tumours continue to be the major subtype in this part of the  world 
and association of risk factors increase the likelihood of an individual developing 
gastric cancer.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY  
  
Gastric cancer is a disease of the older age group.  
 
The association of risk factors is well known and consistent and hint at the 
primordial prevention of the disease.  
 
Distal tumours continue to be the major subtype in this study. Successful preventive 
strategies have to be developed a multischolastic approach should combine 
population screening with molecular biological techniques that are being developed.  
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“CLINICAL STUDY ON INCIDENCE,PATHOLOGICAL PATTERN AND 
MANAGEMENT OF GASTRIC CARCINOMA IN GOVT. RAJAJI 
HOSPITAL,MADURAI 
 
 
PROFORMA  
 
 
NAME                                                                               CASE NO: 
                                                           
 
AGE                                                                                  D.O.A 
 
SEX                                                                                    D.O.S 
 
OCCUPATION                                                                   D.O.D 
 ADDRESS                                                                         HOSPITAL 
 
SOCIOECONOMIC STATUS 
 
CHIEF COMPLAINTS: 
 
 
      Mass per abdomen: 
      Pain abdomen: 
      Distension: 
      Loss of weight: 
      Loss of apetite: 
      Localized swelling: 
      Fever: 
     Jaundice: 
     Others: 
 
 
 
HISTORY OF PRESENT ILLNESS: 
 
1) MASS PER ABDOMEN 
Onset: 
Site: 
Duration: 
Progression- sudden increase/sudden decrease/gradual increase/no progression: 
Secondary changes: 
Similar swellings elsewhere 
 
 
 2)PAIN ABDOMEN: 
 
Onset: 
Duration: 
Nature-dragging/colicky/dull aching/continuous 
Intensity:mild/severe 
Progression/nonprogression 
Site:localized/generalized 
Aggravating/relieving factor 
Relation to food 
Vomiting 
Radiation 
 
3)DISTENSION: 
 Onset: 
Duration: 
Progression: 
Relation to vomiting 
Relation to pain 
 
4)JAUNDICE 
 
5)CHEST PAIN 
 
Site  
Duration 
Nature 
 
6)COUGH/HEMOPTYSIS 
 
7)FEVER 
 
8)LOSS OF WEIGHT: 
 
9)OTHERS: 
 
 
PAST HISTORY 
 
Any sImilar complaints 
Any previous treatment/surgeries 
History of TB / DM / HTN / COPD 
 
  
PERSONAL HISTORY 
 
Apetite          sleep 
Diet             bowel and bladder habits 
Smoker       alcoholic 
 
 
FAMILY HISTORY 
 
MENSTRUAL HISTORY & OBSTETRIC HISTORY(females) 
 
 
DRUG HISTORY: 
  
GENERAL PHYSICAL EXAMINATION: 
 
Apperence                           vital signs 
Pallor                                      pulse 
Cyanosis                     blood pressure    
Clubbing                respiratory rate 
Jaundice      temperature 
Pedal edema 
Lymphadenopathy 
 
SYSTEMIC EXAMINATION: 
 
EXAMINATION OF ABDOMEN: 
 A) INSPECTION: 
 
Contour of abdomen- fullness/mass-site 
    Flat 
Umbilicus 
          -              position: stretched/everted/pushed 
 
Movements with respiration: 
 
 
Visible pulsations/peristalsis 
 
Dilated veins 
 
Flanks 
 
Skin 
 
Hernia orifices 
 
External genitalia 
 
Renal angles 
 
Supraclavicular fossa 
 
any mass: 
   number 
 shape 
 size 
 site 
 extent 
 surface 
 borders 
 impulse on coughing 
 presseure effects 
 pulsations 
 
 
B)PALPATION: 
 
Local temperature 
 
Tenderness:site 
Mass 
Number 
Shape 
Size 
Site 
Extent 
Surface 
Borders 
Movement with respiration 
Consistency : soft / cystic / firm / hard 
Pulsations 
Mobility:  free/restricted 
   Vertical/horizontal 
Plane: parietal / intraperitoneal / retroperitoniel 
Organomegaly 
Guarding/rigidity 
Palpation of hernial orifices 
External genitalia 
Any other mass 
 
c) PERCUSSION 
 
percussion note over mass 
whole abdomen:reonant/dull 
free fliud:normal /obliterated 
dullness over renal angle 
 
 
D)AUSCULTATION: 
 
Bowel sounds 
Bruit 
 
  E) PER RECTAL 
 
  F) PER VAGINAL 
 
  G) EXTERNAL GENITALIA 
 
  H) SPINAL EXTREMITIES 
 
  I) SUPRACLAVICULAR LYMPHNODES 
 
 
RESPIATORY SYSTEM 
  
CARDOVASCULAR SYSTEM 
 
 
CENTRAL NERVOUS SYSTEM 
 
 
MUSCULOSKELETAL SYSTEM 
 
 
CLINICAL DIAGNOSIS: 
 
 
 
  
 
 
 
 
 
 
 
 
Fig. 7 Endoscopic photograph showing ulceroproliferative growth   
in antrum  
  
 
  
 
Fig.8 Endoscopic photograph showing early gastric cancer   
  
  
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 9 Photograph showing gastric cancer invading the posterior wall and 
perforating it 
 
 
Fig. 10  Photograph showing palliative anterior gastrojejunostomy 99 
 
 
 
 
 
 
 
 Fig. 11 Photograph showing partial gastrectomy specimen  
 
 
 
 
 
 
Fig12Photograph showing opened partial gastrectomy specimen100  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
NO. NAME AGE SEX IP.NO PLACE DOA DOS DOD SYMPTOMS SE STATUS DIET SMOKED 
F 
SPICY FRUITS S
M
OK
E 
ALC
OH
OL 
A
N
E
M
IA 
JAU
NDI
CE 
VGP MAS
S 
BLOOD 
GROU
P 
MACRO HPE 
1 MARIAMMAL 50 F 11579 MADURAI 2.8.13 4.8.13 12.8.13 abcde LOW MIXED - + + - - + - - + A II WELL 
2 LINGAM 70 M 82977 VIRUDHUNAGAR 5.8.13 7.8.13 15.8.13 abcde LOW MIXED - + + - - - - - - A IV WELL 
3 MUNIYANDI 65 M 2777 ARUPPUKOTTAI 17.8.13 19.8.13 27.8.13 bdeh LOW MIXED + + + - - + - - - O II POOR 
4 MUTHUKARUPPAN 58 M 14612 DINDUGAL 21.8.13 23.8.13 1.9.13 abdch MID MIXED - - - - + - - - - A III WELL 
5 KALUVAYEE 58 F 21245 KOTTAMPATTI 29.8.13 31.8.13 9.9.13 acd LOW MIXED + + + + - + - - + B IV POOR 
6 SANJEEVI 54 M 21234 MADURAI 7.9.13 9.9.13 17.9.13 abcd MID MIXED - + + + + - - - - A III POOR 
7 LAKSHMI 42 F 26999 KOTTAMPATTI 10.9.13 12.9.13 20.9.13 adeg LOW MIXED - + + + - - - - - A II WELL 
8 VELUTHAAI 45 F 31945 DINDUGAL 17.9.13 19.9.13 27.9.13 abc LOW MIXED - + + - + + - - + O II WELL 
9 MEYYAPPAN 60 M 33972 ARUPPUKOTTAI 24.9.13 26.9.13 4.10.13 acde LOW MIXED + + - - - + - + - A II WELL 
10 ARUMUGAM 59 M 49199 VIRUDHUNAGAR 5.10.13 7.10.13 15.10.13 abcdg MID MIXED - - + + - - - - - AB IV POOR 
11 MOHAN 62 M 50947 SIVAKASI 9.10.13 11.10.13 19.10.13 beh LOW MIXED + + - - + + - - - A I MOD 
12 MANICKAM 50 M 50128 ARUPPUKOTTAI 19.10.13 21.10.13 29.10.13 acdh LOW MIXED - - + + - - - - + O II WELL 
13 PAPPA 52 M 76215 MADURAI 22.10.13 24.10.13 2.11.13 bcd LOW MIXED - + + - - + - - - A II WELL 
14 KAMATCHI 60 F 83629 SIVAGANGAI 2.11.13 4.11.13 12.11.13 aceh MID MIXED + - + - - + - + - AB IV MOD 
15 RAMAN  55 M 723 DINDUGAL 7.11.13 9.11.13 17.11.13 abd LOW MIXED - + - + + - - - + A III WELL 
16 PALANISAMY 66 M 93863 SIVAGANGAI 9.11.13 11.11.13 19.11.13 abe LOW VEG - + + + - + - - - O II MOD 
17 KALEESWARI 35 F 1860 KOTTAMPATTI 15.11.13 17.11.13 25.11.13 bcd LOW MIXED - + + - + + - - + A IV WELL 
18 MARAVARMAN 50 M 9107 VIRUDHUNAGAR 21.11.13 23.11.13 1.12.13 ace MID MIXED + + + + - + - - - O III MOD 
19 PEER MOHAMMED 70 M 12045 ARUPPUKOTTAI 24.11.13 26.11.13 4.12.13 abd MID MIXED - - - - - - - - + A II WELL 
20 PANDIYARAJA 67 M 13600 SIVAKASI 6.12.13 8.12.13 16.12.13 acd LOW MIXED - - + - + + - - - A II MOD 
21 ANNAMALAI 75 M 17451 MADURAI 9.12.13 11.12.13 19.12.13 abcdh LOW MIXED + + + - - + - - + AB IV WELL 
22 JANARTHANAN 56 M 40884 MADURAI 17.12.13 19.12.13 27.12.13 adeh LOW MIXED + + + - + + - - + A II WELL 
23 KARUPPAYYA 61 M 44498 KOTTAMPATTI 25.12.13 27.12.13 5.1.14 abcg LOW MIXED - + + + + + - + - O III POOR 
24 NATARAJ 65 M 51369 DINDUGAL 2.1.14 4.1.14 12.1.14 abd LOW MIXED - + + - - - - - - A II WELL 
25 NAGALAKSHMI 45 F 58329 ARUPPUKOTTAI 6.1.14 8.1.14 16.1.14 abch MID MIXED - + - + - + - - - B II WELL 
26 SILAYAPPAN 78 M 70926 SIVAGANGAI 10.1.14 12.1.14 20.1.14 abdgh LOW MIXED + + + - + + - + + O III WELL 
27 CHINNAIRULAN 61 M 90521 VIRUDHUNAGAR 14.1.14 16.1.14 24.1.14 bce LOW MIXED - + + + + - - - - O IV WELL 
28 PANDIYAMMAL 58 F 5224 SIVAKASI 20.1.14 22.1.14 30.1.14 acd LOW VEG - - + + + + - - - A II MOD 
29 RASAKILI 56 M 17937 KOTTAMPATTI 22.1.14 24.1.14 2.2.14 abd MID MIXED + + - - - + - - - B II MOD 
30 THONDHIPILLAYAR 29 M 32105 MADURAI 29.1.14 31.1.14 9.2.14 abced LOW MIXED - + + + - + - - - O II POOR 
31 GOPALAKRISHNAN 38 M 44739 VIRUDHUNAGAR 2.2.14 4.2.14 12.2.14 bc LOW MIXED - + + - - - - - + A IV WELL 
32 PAPPATHY 52 F 43499 ARUPPUKOTTAI 7.2.14 9.2.14 17.2.14 abde LOW MIXED - + - - + + - - - B II WELL 
33 KUMARAYEE 65 F 66121 SIVAGANGAI 17.2.14 19.2.14 27.2.14 ad LOW VEG - - + - - + - - - A II MOD 
34 VEMBULAKKAL 38 F 73509 KOTTAMPATTI 26.2.14 28.2.14 6.3.14 acf LOW MIXED - + + + + - + - + O IV WELL 
35 REVATHY 36 F 69916 MADURAI 1.3.14 3.3.14 11.3.14 abdc LOW MIXED - + + - + + - - - A III MOD 
36 ANNAVI 45 F 73570 SIVAGANGAI 6.3.14 8.3.14 16.3.14 ade LOW MIXED + + + + + + - - - A II WELL 
37 KAATTURANI 32 F 74160 ARUPPUKOTTAI 11.3.14 13.3.14 21.3.14 abc LOW MIXED - + - - - - - + - O IV WELL 
38 ANNAKILI 48 F 72454 MADURAI 21.3.14 23.3.14 31.3.14 bcd LOW MIXED - - + + + + - - - A II WELL 
39 PONNUTHAAI 60 F 68467 SIVAGANGAI 25.3.14 27.3.14 5.4.14 ace LOW MIXED + + + - + + - - + A I MOD 
40 KAALIAMMAL 78 F 62358 VIRUDHUNAGAR 5.4.14 7.4.14 15.4.14 abcd LOW MIXED - + + + + + - - - A III WELL 
41 CHELLAMUTHU 45 M 77973 SIVAKASI 13.4.14 15.4.14 23.4.14 cde LOW MIXED - + + - + - - + - B II MOD 
42 KANNAMMAL 60 F 77997 DINDUGAL 21.4.14 23.4.14 1.5.14 abh LOW MIXED - + + + - + - - + A IV POOR 
43 THAVAMANI 42 F 73943 SIVAKASI 4.5.14 6.5.14 14.5.14 acbhd MID MIXED + + + + - + - - - B II WELL 
44 GANESAN 49 M 78725 ARUPPUKOTTAI 12.5.14 14.5.14 22.5.14 ace LOW VEG - + + - - + - - + O II WELL 
45 POTHUMANI 36 F 78738 VIRUDHUNAGAR 19.5.14 21.5.14 29.5.14 bcd LOW MIXED + + - + + - - - - B III WELL 
46 NATARAJAN 59 M 80596 SIVAGANGAI 22.5.14 24.5.14 2.6.14 bde LOW MIXED - - + - - + - - + AB IV MOD 
47 RAAKKU 40 F 3600 DINDUGAL 13.6.14 15.6.14 23.6.14 abcd LOW MIXED - + + + - + - - - B IV WELL 
48 VELLAISAMY 77 M 83665 SIVAGANGAI 23.6.14 25.6.14 3.7.14 ade MID VEG + + + - - + - + - AB III POOR 
49 DHANABALAN 50 M 83755 MADURAI 7.7.14 9.7.14 17.7.14 abcdg LOW MIXED - + + + + + - - + B IV WELL 
50 PUSHPAM 30 F 21995 MADURAI 15.7.14 17.7.14 25.7.14 aeh LOW MIXED - + + + - + - - - AB II WELL 
 
 
 
 
 
 
 
 
KEY TO MASTER CHART  
  
APL- Above Poverty Line              I- Infiltrative  
BPL- Below poverty Line   IO- Inoperable  
NS- Nothing Significant               JJ- Jejunojejunostomy  
M- Mix ed                           LC- Lesser curvature   
V- Vegetarian     LS- Liver secondaries  
F- Frequent                          MA - Minimal Ascites  
O- Occasional     MRD- Medical Renal Disease    
Mo- Moderate     O- Operable  
A- Ascites      P- Poor        
D- Deh ydration     B- Body   
PA- Pyloric Antrum    C- Cardia   
PALN- Paraaortic Lymph nodes  D- Diffuse  
PE- Pleural effusion      DC- Decreased capacity   
DS- Dilated Stomach     Per- Perforation   
EL- Emergency Laparotomy   Po- Polypoidal  
F- Fundus       FJ- Feeding Jejunostomy              
PO- Pyloric Obstruction    G- Growth  
GEJ- Gastro-oesophageal junction  GC- Greater curvature  
SYMTOMS 
a- Abdominal pain 
b- Nausea/vomiting 
c- Weight loss 
d- Anorexia 
e- Early satiety 
f- Jaundice 
g- Dysphagia 
h- malena 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   
 
